Novo Nordisk Faces Setback With CagriSema Trial: Impact on Competitors and Market Trends
Novo Nordisk (NVO), a global leader in pharmaceuticals, experienced a significant decline in its stock value following disappointing trial results for its experimental weight-loss drug, CagriSema. This development has sparked…